Development of a live vaccine for gut health in poultry. Development of a live vaccine for gut health in poultry. The project aims to develop a live vaccine against necrotic enteritis, a disease of poultry estimated to cost the global poultry industry $5-6 billion USD/annum. It builds on work that has demonstrated the efficacy of an experimental vaccine. The proven antigen, NetB, will be expressed in live delivery vehicles, including the apicomplexan parasite Eimeria and several bacteria strains ....Development of a live vaccine for gut health in poultry. Development of a live vaccine for gut health in poultry. The project aims to develop a live vaccine against necrotic enteritis, a disease of poultry estimated to cost the global poultry industry $5-6 billion USD/annum. It builds on work that has demonstrated the efficacy of an experimental vaccine. The proven antigen, NetB, will be expressed in live delivery vehicles, including the apicomplexan parasite Eimeria and several bacteria strains particularly suited to use in chickens. Comparative analysis of the different vaccine vehicles will allow evaluation of the relative advantages and disadvantage of the different vehicles for delivery of heterologous vaccine antigens, thus informing the choice of appropriate vectors for this and other vaccine applications.Read moreRead less
Reducing the health & economic burden of Campylobacter using a live vaccine. The aim of the project is to develop a vaccine to reduce Campylobacter bacteria in chickens. Campylobacters cause disease in both poultry and humans. Poultry products are the most common source of human infections. By reducing Campylobacter in poultry, the transfer to humans will be reduced. The expected outcomes arising from this work will be a reduction of the economic burden of poultry losses, in an Australian indust ....Reducing the health & economic burden of Campylobacter using a live vaccine. The aim of the project is to develop a vaccine to reduce Campylobacter bacteria in chickens. Campylobacters cause disease in both poultry and humans. Poultry products are the most common source of human infections. By reducing Campylobacter in poultry, the transfer to humans will be reduced. The expected outcomes arising from this work will be a reduction of the economic burden of poultry losses, in an Australian industry valued at $2.8 billion/year, and an improvement in food safety, thus helping to reduce the burden of foodborne illness, estimated to be $1.2 billion dollars/year. This project is, therefore, poised to benefit the Australian economy, specifically primary producers and the general public, by targeted vaccination of poultry.Read moreRead less